Biosimilar Newsletter Archive
-
05.20.22 -- Enhancing The Patient Experience During Subcutaneous Biologic Delivery
5/20/2022
05/20/22 Biosimilar Development Newsletter
-
05.19.22 -- Post-COVID Supply Chain Strategies For BioPharma
5/19/2022
05/19/22 Biosimilar Development Newsletter
-
05.15.22 -- Celltrion's Remsima Wins Brazilian Tender
5/15/2022
05/15/22 Biosimilar Development Newsletter
-
05.12.22 -- Celltrion's Remsima Wins Brazilian Tender
5/12/2022
05/12/22 Biosimilar Development Newsletter
-
05.06.22 -- mRNA Manufacturing Strategies
5/6/2022
05/06/22 Biosimilar Development Newsletter
-
05.05.22 -- CMC & Quality Considerations When Engaging Your CDMO
5/5/2022
05/05/22 Biosimilar Development Newsletter
-
05.03.22 -- New Episodes: Allogeneic CAR-T Therapies, Antibodies for Severe Allergies, and more.
5/3/2022
05/03/22 Biosimilar Development Newsletter
-
04.28.22 -- Amgen's Ph3 Biosimilar Stelara Trial Boasts Positive Results
4/28/2022
04/28/22 Biosimilar Development Newsletter
-
04.21.22 -- Amneal Achieves Second U.S. Biosimilar Approval
4/21/2022
04/21/22 Biosimilar Development Newsletter
-
04.14.22 -- BioPharma Deal-Making In 2022: Key Trends
4/14/2022
04/14/22 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more